Targeting PCSK9 in clinical practice: Guidance & future10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam University Medical Centers, The Netherlands
Video navigation menu
- Issues surrounding lipid lowering therapy 1:10
- Low-frequency injectable siRNA PCSK9 inhibition 4:55
- Statin intolerance as major gap in ASCVD prevention 7:09
- Other lipid targets to pursue 9:58
This lecture by prof. John Kastelein was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.
Prof. John Kastelein, MD – Professor of Medicine, Department of Vascular Medicine at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands, where he holds the Strategic Chair of Genetics of Cardiovascular Disease
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Amgen and Sanofi-Regeneron.